

Kristen N. Ganjoo, MD
Stanford University Medical Center
875 Blake Wilbur Drive, CC2228
Stanford, CA 94305-5821
(650)498-6000

PROFESSIONAL /ACADEMIC APPOINTMENTS

6/15/2000-4/15/2004 Assistant Professor of Medicine
Hematology/Oncology, Indiana University Medical Center

5/1/2004-9/30/2011 Staff Oncologist
Palo Alto Veterans Administration

5/1/2005-1/31/2014 Assistant Professor of Medicine
Oncology, Stanford University Medical Center

2/1/2015-1/31/2025 Associate Professor of Medicine
Oncology, Stanford University Medical Center

TRAINING

1994-1995 Internal Medicine Internship; Indiana University Medical Center,
Indianapolis, IN

1995-1997 Internal Medicine Residency; Indiana University Medical Center,
Indianapolis, IN

1997-2000 Hematology/Oncology Fellowship; Indiana University Medical
Center, Indianapolis, IN

EDUCATION

1985-1987 De Anza College, Cupertino, CA

1987-1989 Bachelor of Science, Biology
University of California, Davis

1989-1994 Doctor of Medicine
University of South Alabama College of Medicine
Mobile, AL

BOARD CERTIFICATION

1998 American Board of Internal Medicine (ABIM)
2000 Medical Oncology Board (ABIM)

October 3, 2020

2010 Medical Oncology Recertification (ABIM)

PROFESSIONAL SOCIETIES

1998-present	American Society of Clinical Oncology (ASCO)
2000-2010	American Society of Hematology (ASH)
2004-present	Eastern Cooperative Oncology Group (ECOG)
2008-2012	International Extra-nodal Lymphoma Society Group
2008-present	Connective Tissue Oncology Society (CTOS)
2008-present	Sarcoma Alliance for Research through Collaboration (SARC)
2009-present	Association of Northern California Oncologists (ANCO)
2010-present	National Comprehensive Cancer Network (NCCN)

PROFESSIONAL APPOINTMENTS

2004-2010	ECOG, Core Committee
2009-present	NCCN Guidelines Committee for Gastrointestinal Stromal Tumor
2009-present	NCCN Guidelines Committee for Soft Tissue Sarcoma
2010	NCCN Grant Proposal Scientific Review Board
2011-2015	ASCO Sarcoma Committee for 2012-2015 Scientific Meetings
2011-2018	SARC Scientific Review Committee
2014-2016	ANCO, Board of Directors
2015	CTOS Abstract Review Committee
2021	NCI SPORE (P50) II Review Committee

HOSPITAL AND UNIVERSITY COMMITTEES

2007-2009	Scientific Review Committee, Palo Alto Veterans Administration
2010-present	Stanford Cancer Center Sarcoma Program Physician Leader
2010-present	Stanford Sarcoma Clinical Research Committee Director
2012-present	Stanford Institutional Review Board
2012-present	Stanford Cancer Institute Scientific Review Board
2012-present	Director, Stanford Sarcoma Program

EDITORIAL ACTIVITIES

2014-present	Sarcoma Research, International-Reviewer
2014-present	Sarcoma Research, International- Editorial Board

AWARDS

2/12/2013	Stanford Cancer Institute Outstanding Performance in Clinical Research
2/26/2013	Stanford Cancer Center Award for Disease Management Group
11/22/2013	Writing in the Sciences-Completed with Distinction

TEACHING ACTIVITY

May 1, 2021

2009-2013	Mentor, Stanford Immersion in Medicine Series (SIMS)
2018-present	Mentor, Harker High School Premed Club
2019-present	Mentor, Internal Medicine Resident, Dr. Maggie Zhou

PEER-REVIEWED PUBLICATIONS

1. Kesler KA, Rieger KM, **Ganjoo KN**, Sharma M, Fineberg NS, Einhorn LH, and Brown JW. Primary Mediastinal Nonseminomatous Germ Cell Tumors: The Influence of Post-Chemotherapy Pathology on Long-Term Survival after Surgery. *J Thorac Cardiovasc Surg* 1999; 118:692-701.
2. **Ganjoo KN**, Chan RJ, Sharma M, and Einhorn LH. PET Scans in the evaluation of post-chemotherapy (PC) residual masses in patients with seminoma. *J Clin Oncol* 1999; 17(11):3457-60.
3. **Ganjoo KN**, Loyal JA, Cramer HM, and Loehrer PJ. Metastatic Adenocarcinoma to the Patella. *J Clin Oncol* 1999; 17(9):2995-7.
4. **Ganjoo KN**, Rieger KM, Kesler KA, Sharma M, Heilman DK, and Einhorn LH. Results of Modern Therapy in Mediastinal Non-Seminomatous Germ Cell Tumors (PMNSGCT): The Indiana University Experience. *Cancer* 2000; 88:1051-6.
5. **Ganjoo KN**, Foster RA, Michael H, Donohue JP, and Einhorn LH. Germ cell tumor (GCT) associated Primitive Neuroectodermal Tumors (PNET). *J Urol* 2001; 165(5):1514-6.
6. **Ganjoo KN**, Gordon MS, Sandler AB, Fife K, Poirier S, Warner R, and Loehrer PJ. A Phase I study of weekly Gemcitabine (G) and Docetaxel (D) in patients with Advanced Cancer: A Hoosier Oncology Group Study. *Oncology* 2002; 62:299-304.
7. Shafqat A, Yum MN, Abanour R, **Ganjoo KN**. Unusual locations of involvement by malignancies. Case study: Testicular Plasmacytoma. *J Clin Oncol* 2003; 21(17):3368-9.
8. Schneider BP, **Ganjoo KN**, Seitz DE, Picus J, Fata F, Stoner C, Loehrer PJ. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group Study. *Oncology* 2003; 65:218-23.
9. **Ganjoo, KN**, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, Bufill J, Williams S, Cripe LD. Phase II study of single-agent gemcitabine in refractory or relapsed low-grade non-Hodgkin's lymphoma. A Hoosier Oncology Group Study. *Am J of Clin Oncol* 2005; 28(2):169-72.

10. **Ganjoor KN**, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ. Rituximab, Bevacizumab and CHOP (RA-CHOP) in Untreated Diffuse Large B-cell Lymphoma: Safety, Biomarker and Pharmacokinetic Analysis. *Leuk Lymphoma* 2006; 47(6):998-1005.
11. Frankel AE, Surendranathan A, Black JH, White A, **Ganjoor KN**, and Cripe LD. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. *Cancer* 2006; 106:2158-64.
12. **Ganjoor KN**, Advani R, Mariappan R, McMillan A, Horning S. Non-Hodgkin's Lymphomas of the Breast. *Cancer* 2007; 110:25-30.
13. **Ganjoor KN**, Moore AM, Orazi A, Sen JA, Johnson CS, An CS. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: A retrospective study of 97 patients. *J Cancer Res Clin Oncol* 2008; 134(3): 381-7.
14. Espinosa I, Beck A, Lee CH, Subramanian S, Zhu S, Montgomery KD, Marinelli RJ, **Ganjoor KN**, West RB, Nielsen TO, Gilks CB, van de Rijn M. Coordinate Expression of Colony Stimulating Factor-1 (CSF1) and CSF1 Related Proteins is Associated with Poor Prognosis in Uterine and Extra-uterine Leiomyosarcoma. *Am J Pathol* 2009; 174(6): 2347-56.
15. **Ganjoor KN**, Demetri G, Jacobs C, Patel S. Acute Myeloid Leukemia in GIST patients treated with Gleevec. *Leuk & Lymphoma* 2009; 50(11):1882-4.
16. Brar R, West R, Witten D, Raman B, Jacobs C, **Ganjoor KN**. Breast angiosarcoma: Case series and expression of vascular endothelial growth factor. *Case reports in Oncology* 2009; 2:242-50.
17. **Ganjoor KN**, Raman R, Sobel RA, Pinto HA. Opportunistic Enteroviral Meningoencephalitis: An Unusual Treatable Complication of Rituximab Therapy. *Leuk Lymphoma* 2009; 50 (4): 673-5.
18. Iagaru A, Mitra ES, **Ganjoor KN**, Knox S, Goris ML. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) Therapy of low grade refractory/relapsed non-Hodgkin's lymphoma. *Molecular Imaging & Biology* 2010; 12:198-203.
19. Kahl B, Bartlett N, Leonard J, Chen L, **Ganjoor KN**, Williams M, Czuczman M, Robinson K, Joyce R, van der Jagt R, Cheson B. Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkins lymphoma: results from a multicenter study. *Cancer* 2010; 116:106-14.
20. Clément-Duchêne C, Krupitskaya Y, **Ganjoor KN**, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. A

phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. *J Thorac Oncol.* 2010; 5(11):1821-5.

21. **Ganjoo KN**, Witten D, Patel M, Espinosa I, West R, La T, van de Rijn, Jacobs C. The predictive value of tumor associated macrophages in leiomyosarcoma. *Am J Clin Oncol* 2011; 34: 82–6.
22. **Ganjoo KN**, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP. A Phase I study of the Safety and Pharmacokinetics of the Hypoxia-activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma. *Oncology* 2011; 80:50-6.
23. Pappo AS, Patel SR, Crowley J, Reinke D, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, **Ganjoo KN**, Schuetze SM, Juergens H, Leahy M, Geoerger B, Benjamin RS, Helman LJ, Baker LH. R1507, A Monoclonal Antibody to the Insulin-Like Growth Factor-1 receptor (IGF-1R) is an active and promising agent in Patients with Recurrent or Refractory Ewing's Sarcoma Family of Tumors (ESFT): Results of a Phase II SARC Study. *J Clin Oncol* 2011; 29:4541-7.
24. Advani R, Hong F, Horning SJ, Kahl BS, Manola J, Swinnen LJ, Habermann TM, **Ganjoo KN**. Cardiac Toxicity Associated with Bevacizumab (Avastin) in Combination with CHOP Chemotherapy for Peripheral T Cell Lymphoma in ECOG 2404 Trial. *Leuk Lymphoma* 2012; 53(4):718-20.
25. Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Slapak CA, Smith MR, Link BK, Wooldridge JE, **Ganjoo KN**. Results of a Phase 1 Study of AME-133v (LY2469298) an Fc-Engineered Humanized Monoclonal Antibody, in Low Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma. *Clin Cancer Res.* 2012; 18(5):1395-403.
26. Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, **Ganjoo KN**, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. Maintenance bevacizumab is associated with increased hemoglobin in patients with nonsquamous, non-small cell lung cancer. *Cancer Invest.* 2012; 30(3):231-5.
27. Henry E, Villalobos V, Million L, Jensen KC, West R, **Ganjoo KN**, Lebensohn A, Ford JM, Telli ML. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with li-fraumeni syndrome. *J Natl Compr Canc Netw.* 2012; 10(8):939-42.
28. **Ganjoo KN**, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LD, Habermann TM, Kahl BS, Advani RH. Bevacizumab and CHOP (A-CHOP) in

Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms: An Eastern Cooperative Group Study (E2404). *Leuk Lymphoma* 2013, *Leuk Lymphoma* 2014; 55(4):768-72.

29. **Ganjoon KN**, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner AJ, D'Adamo D, McMillan A, Demetri GD, and George S. A Multicenter Phase II Study of Pazopanib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) following failure of at least Imatinib and Sunitinib. *Ann Oncol* 2014; 25 (1): 236-40.
30. Levy R, **Ganjoon KN**, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Denney DW, and Alizadeh AA. Active Idiotypic Vaccination versus Control Immunotherapy for Follicular Lymphoma. *J Clin Oncol.* 2014 Jun 10; 32(17):1797-803.
31. Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Georger B, **Ganjoon KN**, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ. Phase II Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Patients with Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas: Results of a Sarcoma Alliance for Research through Collaboration Study. *Cancer.* 2014;120(16):2448-56.
32. Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, **Ganjoon KN**. A Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma. *J Clin Oncol.* 2014;32(29):3299-306.
33. Martin-Broto J, Cleeland CS, Glare PA, Engellau J, Skubitz KM, Blum RH, **Ganjoon KN**, Staddon A, Dominkus M, Feng A, Qian Y, Braun A, Jacobs I, Chung K, Atchison C. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study. *Acta Oncol.* 2014;19:1-7.
34. **Ganjoon KN**, de Vos S, Pohlman BL, Flinn IW, Forero-Torres A, Enas NH, Cronier DM, Dang NH, Foon KA, Carpenter SP, Slapak CA, Link BK, Smith MR, Mapara M, Wooldridge J. Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Monoclonal anti-CD20 Antibody, in Low Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma. *Leuk Lymphoma.* 2015;56(1):42-8.
35. Guo X, Young Jo V, Mills AM, Zhu SX, Lee CH, Espinosa I, Nucci MR, Varma S, Forgó E, Hastie T, Anderson S, **Ganjoon K**, Beck AH, West RB, Fletcher C, van

- de Rijn M. Clinically relevant molecular subtypes in leiomyosarcoma. *Clin Cancer Res.* 2015;21(15):3501-11.
36. Worhunsky DJ, Gupta M, Gholami S, Tran TB, **Ganjoo KN**, van de Rijn M, Visser BC, Norton JA, Poultides GA. Leiomyosarcoma: One disease or distinct biologic entities based on site of origin? *J Surg Oncol.* 2015 Jun;111(7):808-12.
37. Park MJ, **Ganjoo KN**, Ladd AL. Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report *J Hand Surg Am.* 2015;40(8):1620-4.
38. Jackson T, Mosci C, von Eyben R, Mitra E, **Ganjoo KN**, Biswal, S, Gambhir SS, Iagaru A. Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients. *Clin Nucl Med* 2015;40(9):720-4.
39. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem MM, Elias A, **Ganjoo KN**, Tawbi HA, Van Tine B, Spira A, Dean A, Khokhar NZ, Park Y, Knoblauch RE, Parekh TV, Maki RG, and Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma Following Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. *J Clin Oncol.* 2016 ;34(8):786-93.
40. Chawla SP, Papai Z; Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khaml K, **Ganjoo K**, Nagarkar R, Wieland S; Levitt DJ. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma A Phase 2b Randomized Clinical Trial. *JAMA Oncol.* 2015 ,1(9):1272-80.
41. Poultides GA, Tran TB, Zambrano E, Janson L, Mohler DG, Mell MW, Avedian RS, Visser BC, Lee JT, **Ganjoo K**, Harris EJ, Norton JA. Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study. *Ann Surg.* 2015 Oct;262(4):632-40.
42. Chawla SP, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A, Khamly K, **Ganjoo K**, Nagarkar R, Wieland S, Levitt DJ. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. *JAMA Oncol.* 2015 ,1(9):1272-80.
43. Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, **Ganjoo KN**, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH. SARCO09: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. *Cancer.* 2016,122(6):868-74.

44. Ghanouni P, Dobrotwir A, Bazzocchi A, Bucknor M, Bitton R, Rosenberg J, Telischak K, Busacca M, Ferrari S, Albisinni U, Walters S, Gold G, **Ganjoo K**, Napoli A, Pauly KB, Avedian R. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. *Eur Radiol.* 2017 ;27(2):732-740.
45. Schuetze SM, Bolejack V, Choy E, **Ganjoo KN**, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. *Cancer.* 2017;123(1):90-97.
46. Martin P, Chen Z, Cheson BD, Robinson KS, Williams M, Rajguru SA, Friedberg JW, van der Jagt RH, LaCasce AS, Joyce R, **Ganjoo KN**, Bartlett NL, Lemieux B, VanderWalde A, Herst J, Szer J, Bar MH, Cabanillas F, Dodds AJ, Montgomery PG, Pressnail B, Ellis T, Smith MR, Leonard JP. Long-term outcomes, secondary malignancies, and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. *Br J Haematol.* 2017 Jul;178(2):250-256.
47. Tap WD, Papai Z, Van Tine BA, Attia S, **Ganjoo KN**, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan, CW, Alcindor T, Garcia del Muro XF, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. An International Randomised Phase 3 Trial of Doxorubicin plus Evofosfamide vs Doxorubicin Alone in Locally Advanced, Unresectable or Metastatic Soft Tissue Sarcoma: TH CR-406/SARC 21. *Lancet Oncol.* 2017;18(8):1089-1103.
48. Hensley ML, Patel SR, von Mehren M, **Ganjoo K**, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki R, Demetri GD. Title: Efficacy and Safety of Trabectedin or Dacarbazine in Patients with Advanced Uterine Leiomyosarcoma after Failure of Anthracycline-based Chemotherapy: Subgroup Analysis of a Phase 3, Randomized Clinical Trial. *Gynecol Oncol.* 2017 doi: 10.1016/j.ygyno.2017.06.018.
49. Moding E, Million L, Avedian RS, Ghanouni P, Kunder C, **Ganjoo K**. Concurrent imatinib and radiation therapy for unresectable and symptomatic desmoid tumors. *Sarcoma* 2017; 2316839. doi: 10.1155/2017/2316839
50. Porter JB, Rosenthal EL, Winget M, Smith AS, Seshadri SB, Vetteth Y, Kiamanesh EF, Badwe A, Advani RH, Buyyounouski MK, Coutre S, Dirbas F, Divi V, Dorigo O, **Ganjoo KN**, Johnston LJ, Recht LD, Shrager JB, Skinner EC, Swetter SM, Visser BC, Blayney DW. Improving Care with a Portfolio of

Physician-led Cancer Quality Measures at an Academic Center. *J Oncol Pract.* 2017;13(8):e673-e682.

51. Yurkiewicz IR, **Ganjoor KN**, Iagaru A. Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT. *Clin Nucl Med.* 2018;43(4):e113-e114.
52. Seetharam M, Kolla KR, **Ganjoor KN**. Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma. *Future Oncol.* 2018;14(23):2323-2333
53. Bui N, Kamat N, Ravi V, Chawla S, Lohman M, **Ganjoor KN**. A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma. *Rare Tumors.* 2018 Apr 23;10:2036361318771771. eCollection 2018.
54. Wu Y, Million L, Moding EJ, Scott G, Berry M, **Ganjoor KN**. The impact of postoperative therapy on primary cardiac sarcoma. *J Thorac Cardiovasc Surg.* 2018;156(6):2194-2203
55. Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, **Ganjoor KN**, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. *JAMA Oncol.* 2018 Jun 1;4(6):814-820.
56. Kamat NV, Million L, Yao DH, Donaldson SS, Mohler DG, van de Rijn M, Avedian RS, Kapp DS, **Ganjoor KN**. The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University. *Am J Clin Oncol.* 2018 Dec 15. doi: 10.1097
57. Przybyl J, Chabon JJ, Spans L, **Ganjoor KN**, Vennam S, Newman AM, Forgó E, Varma S, Zhu S, Debiec-Rychter M, Alizadeh AA, Diehn M, van de Rijn M. Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. *Clin Cancer Res.* 2018;24(11):2688-2699.
58. Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, **Ganjoor K**, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *Lancet.* 2019;394(10197):478-87.
59. Davis LE, Bolejack V, Ryan CW, **Ganjoor KN**, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF,

Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. *J Clin Oncol.* 2019;37(16):1424-31.

60. Bui NQ, Przybyl J, Trabucco SE, Frampton G, Hastie T, van de Rijn M, **Ganjoor KN**. A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis. *Clin Sarcoma Res.* 2019;9:12.
61. Nezhat C, Vu M, Vang N, **Ganjoor K**, Karam A, Folkins A, Nezhat A, Nezhat F. Endometriosis Malignant Transformation Review: Rhabdomyosarcoma Arising From an Endometrioma. *JSLs.* 2019;23(4):e2019.00038.
62. Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, **Ganjoor KN**, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL; ANNOUCE Investigators. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUCE Randomized Clinical Trial. *JAMA.* 2020 Apr 7;323(13):1266-1276.
63. Przybyl J, Spans L, Lum DA, Zhu S, Vennam S, Forgó E, Varma S, **Ganjoor K**, Hastie T, Bowen R, Debiec-Rychter M, van de Rijn M. Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas. *JCO Precis Oncol.* 2019;3:PO.18.00409.
64. Singh R, Stienen MN, **Ganjoor K**, Kolahi KS, Cayrol R, Charville GW, Born DE, Zygourakis CC. Tenosynovial giant cell tumor of the suboccipital region - A rare, benign neoplasm in this location. *J Clin Neurosci.* 2020;78:413-415.
65. Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, **Ganjoor KN**, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARCO24 Study. *Oncologist.* 2020;25(11):e1655-62.
66. Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, **Ganjoor K**, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. *J Clin Oncol.* 2020;38(28):3294-3303.
67. Gutkin PM, **Ganjoor KN**, Lohman M, von Eyben R, Charville GW, Nazerli RS, Dirbas FM, Horst KC. Angiosarcoma of the Breast: Management and Outcomes. *Am J Clin Oncol.* 2020;43(11):820-825

68. Zhou M, Bui N, Bolleddu S, Lohman M, Becker HC, **Ganjoo K**. Immunotherapy. Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review. *Immunotherapy* 2020;12(18):1303-1312.
69. Zhou M, Ko CK, Charville GW, **Ganjoo KN**. Sinonasal FUS-ERG-rearranged Ewing sarcoma mimicking glomangiopericytoma. *Case Rep Oncol* 2020;13:1393-1396.
70. Zhou M, Bui N, Lohman M, van de Rijn M, Hwang G, **Ganjoo K**. Long-term remission with ipilimumab/nivolumab in two patients with different soft tissue sarcoma subtypes and no PD-L1 expression. *Case Rep Oncol* 2021;14:459-465.
71. Choi S, Zhou M, Bahrani E, Martin, **Ganjoo KN**, Zaba L. Rare and fatal complication of immune checkpoint inhibition: a case report of hemophagocytic lymphohistiocytosis with severe lichenoid dermatitis. *Br J Haematology* 2021. In Print
72. Brewster R, Purington N, Henry S, Wood D, **Ganjoo K**, Bui N. Evaluation of Absolute Lymphocyte Count at Diagnosis and Mortality Among Patients With Localized Bone or Soft Tissue Sarcoma. *JAMA Netw Open*. 2021;4(3):e210845
73. Pan M, **Ganjoo K**, Karam A. Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report. *Perm J* 2021;25:20.251.
74. Yurkiewicz IR, Zhou M, **Ganjoo KN**, Charville GW, Bolleddu S, Lohman M, Bui N. Management Strategies for Patients with Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course. *AJCO* 2021, In Print.
75. Pan M, Trieu MK, Sidhu M, Yu J, Seto T, **Ganjoo K**. Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma. *Cancers (Basel)*. 2021 Apr 20;13(8):1983.

REVIEWS

1. **Ganjoo KN**. Rationale and Current Studies of VEGF Inhibition in Non-Hodgkin's Lymphoma. *Angiogenesis in Oncology* 2005, 1 (2)12-14
2. **Ganjoo KN**. Antiangiogenesis: A new approach to the treatment of lymphoma. Commentary. *Leuk Lymphoma* 2007; 48(3):454-5
3. **Ganjoo KN**, Wakelee HA. Review of Erlotinib in the treatment of advanced non-small cell lung cancer. *Biologics; Targets & Therapy* 2007; 1(4):335-46

4. **Ganjoo KN**, Patel S. Trabectedin, an anti-cancer drug from the Sea. *Expert Opinion in Pharmacology* 2009; 10(16):2735-43
5. **Ganjoo KN**, Jacobs C. Angiogenesis inhibitors in soft tissue sarcomas. *Cancer* 2010; 116:1177-83
6. **Ganjoo KN**. New developments in targeted therapy for soft tissue sarcoma. *Current Oncology Reports* 2010; 12 (4):261-5
7. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, **Ganjoo KN**, Maki RG, Pisters PWT, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent J, Wayne JD. NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors (GISTs). *J Natl Compr Canc Netw* 2010; 8 Supp 2, S1-41
8. Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, **Ganjoo KN**, Heslin MJ, Hutchinson RJ, Kane JM 3rd, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J; National Comprehensive Cancer Network Soft Tissue Sarcoma Panel. *J Natl Compr Canc Netw* 2010; 8(6):630-74
9. **Ganjoo KN**, Patel S. Current and emerging pharmacological treatments for gastrointestinal stromal tumors. *Drugs* 2011; 71(3):321-30
10. von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, **Ganjoo KN**, George S, Gonzalez R, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz B, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines *J Natl Compr Canc Netw*. 2012; 10(8):951-60
11. **Ganjoo KN**, Patel S. The Treatment Outcome for Adult Patients with Ewing's Sarcoma. *Curr Oncol Rep* 2013; 15(4):372-7
12. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, Delaney TF, **Ganjoo KN**, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H. Soft tissue sarcoma, version 2.2014. *J Natl Compr Canc Netw*. 2014 Apr;12(4):473-83
13. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, **Ganjoo KN**, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD,

Bergman MA, Sundar H. Gastrointestinal stromal tumors, version 2.2014. J Natl Compr Canc Netw. 2014 Jun; 12(6):853-62

14. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU 3rd, **Ganjoor KN**, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(6):758-86
15. Bui N, **Ganjoor K**. Chemotherapeutic Treatment of Localized Ewing's Sarcoma in Adults. Sarcoma Res Int 2017, 4 (1) Online.
16. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, **Ganjoor KN**, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Keedy V, Kim E, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, Morris ZS, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Ruo B, Schuetze S, Tap WD, Wayne JD, Bergman MA, Scavone JL. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 May;16(5):536-563.
17. **Ganjoor KN**. Uterine sarcomas. Curr Probl Cancer. 2019(19):30216-8.
18. von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, **Ganjoor KN**, George S, Gonzalez RJ, Heslin MJ, Homsy J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Meyer C, Pappo AS, Parkes AM, Paz IB, Petersen IA, Poppe M, Riedel RF, Rubin B, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Bergman MA, George GV. NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Netw. 2020;18(12):1604-1612.

BOOK CHAPTERS (2)

1. Gottschalk AR, **Ganjoor KN**, Schupak KD, Phillips TL. Adult Sarcoma: Bone and Soft tissue. In: Hoppe R, Phillips TL, Roach M, eds. Leibel and Phillips Textbook of Radiation Oncology, 3rd Ed. 2010, Saunders, Chapter 59:1324-58
2. Guardino E, **Ganjoor KN**, and Advani R. Treatment approach to mantle cell lymphomas. In: Sekeres M, Bolwell B, and Kalaycio M, eds. Clinical Malignant Hematology 2007. McGraw Hill, New York, Chapter 55:555-65

PRESENTATIONS

STANFORD

May 1, 2021

March 2005 Non-Hodgkin's lymphoma: Medicine Residents noon conference

Dec 2006 Non-Hodgkin's lymphoma- Diagnosis and Management: Medicine Residents noon conference

Aug 21, 2007 ASCO Update 2007: Sarcoma. Cancer Education Seminar Series

Nov 2007 Non-Hodgkin's Lymphoma: Medicine Residents noon conference

Jan 2008 Targeting angiogenesis in lymphomas: Cancer Education Seminar Series

Aug 19, 2008 ASCO Update 2008: Sarcoma. Cancer Education Seminar Series

Jan 2009 Treatment of aggressive lymphomas-Focusing on antiangiogenesis: Nuclear Medicine Grand Rounds

Feb 2009 Antiangiogenesis options for lymphoma: Radiation Oncology Resident lecture

June 2009 Antiangiogenesis options for lymphoma: Nuclear Medicine Grand Rounds

Aug 18, 2009 ASCO Update 2009: Sarcoma. Cancer Education Seminar Series

Nov 2009 Sarcoma review for the internist: Medicine Residents noon conference

June 2010 New targeted therapies for soft tissue sarcoma: Stanford Nuclear Medicine Grand Rounds.

Aug 17, 2010 ASCO Update 2010: Sarcoma. Cancer Education Seminar Series

Aug 30, 2011 ASCO Update 2011: Sarcoma. Cancer Education Seminar Series

Aug 21, 2012 ASCO Update 2012: Sarcoma, Cancer Education Seminar Series

March 8, 2013 Multidisciplinary Management of Cancers Conference: Chair of Sarcoma Tumor Board, Stanford, CA

Sep 2, 2014 ASCO Update 2014: Sarcoma, Cancer Education Seminar Series

Feb 10, 2015 Novel Chemotherapeutic Agents for Soft Tissue Sarcoma, Cancer Education Seminar Series

June 19, 2015 Update-Stanford Sarcoma Program

Aug 25, 2015 ASCO Update 2015: Sarcoma, Cancer Education Seminar Series

May 1, 2021

- Oct 13, 2015 Introduction to Soft Tissue Sarcoma, Medicine Resident Lecture
- Oct 22, 2015 Soft Tissue Sarcoma, Medicine Resident Lecture
- Aug 29, 2017 ASCO Sarcoma Presentation, Cancer Education Seminar Series

EXTERNAL

POSTER PRESENTATIONS

- Dec 6, 2004 Rituximab, CHOP (RACHOP) for patients with untreated diffuse large B cell lymphoma: Poster Presentation, annual meeting, American Society of Hematology, San Diego, CA
- Nov 21, 2005 Results of Phase I/II study of doxorubicin combination with TH-302 in advanced sarcomas: Poster Presentation, annual meeting, Connective Tissue Oncology Society, Boca Raton, FL
- June 1, 2008 Prognostic value of tumor associated macrophages in leiomyosarcoma: Poster Presentation, annual meeting, American Society of Clinical Oncology, Chicago, IL
- Nov 6, 2009 Results of a phase I/II study of doxorubicin combined with TH-302 in metastatic or unresectable soft tissue sarcoma: Poster presentation, annual meeting, Connective Tissue Oncology Society, Miami, FL
- Nov 13, 2010 Phase I/II study of Regin-G for the treatment of sarcomas: Poster Presentation, annual meeting, Connective Tissue Oncology Group, Paris, France
- Nov 2, 2013 A Multicenter Phase II Study of Pazopanib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) following failure of at least Imatinib and Sunitinib: Poster Presentation, annual meeting, Connective Tissue Oncology Society, New York, NY

INVITED TALKS

- June 2007 Paving the way for Progress: Clinical trials in blood cancers: Leukemia & Lymphoma Society sponsored meeting, Palo Alto, CA
- Dec 7, 2007 Targeting angiogenesis in non-Hodgkin's lymphoma: Oral Presentation, annual meeting, American Society of Hematology meeting, Atlanta, GA

May 1, 2021

May 2008 Paving the way for Progress: Clinical trials in blood cancers: Leukemia & Lymphoma Society sponsored meeting, Palo Alto, CA

April 2009 Paving the way for Progress: Clinical trials in blood cancers: Leukemia & Lymphoma Society sponsored meeting, Palo Alto, CA

Nov 8, 2009 Preliminary results of TH-302 in combination with Adriamycin in patients with advanced sarcomas: (Audience: Oncologists and Investors)-Miami, FL

June 4, 2010 Presentation of results of a phase I/II of Adriamycin plus TH302, hypoxia activated pro-drug, in high grade soft tissue sarcomas: semi-annual meeting, Sarcoma Alliance for Research through Collaboration Chicago, IL

Aug 2011 The Multidisciplinary Management of gastrointestinal stromal tumors: Tumor Board for Oncologists and Surgeons (A CME-certified oncology exchange activity), Scottsdale, AZ

April 2012 The Multidisciplinary Management of gastrointestinal stromal tumors: Tumor Board for Oncologists and Surgeons (A CME-certified oncology exchange activity), Salt Lake City, UT

May 2012 Medical Management of Sarcomas: Kaiser Oncology Grand Rounds, Santa Clara, CA

June 2, 2012 Oral discussion of 6 posters presented at the annual meeting, American Society of Clinical Oncology, Chicago, IL

June 26, 2012 Treatment of Soft Tissue Sarcomas: O'Connor Hospital Grand Rounds, San Jose, CA

Oct 4, 2012 Multidisciplinary Management of Soft Tissue Sarcomas: Kaiser Oncology Grand Rounds Webinar

March 2013 Multidisciplinary treatment of gastrointestinal stromal tumors: St. Mary's Hospital, Reno, NV

Oct 5, 2013 Novel and targeted therapies for Sarcomas: Oral presentation, Musculoskeletal Tumor Society, annual meeting of Orthopedic Oncology Surgeons, San Francisco, CA

Feb 3, 2014 Novel and targeted therapies for soft tissue sarcomas: St. Rose Hospital, Hayward, CA

Oct 16, 2014 Hypoxia directed therapy for sarcoma: Prime Oncology CME presentation, Berlin, Germany

May 1, 2021

Nov 1, 2014	Leiomyosarcoma: What's new, Trials and Treatment, LMS Direct Research Foundation, Patient Advocacy Group. San Francisco, CA
Dec 1, 2014	Novel chemotherapeutic agents for soft tissue sarcomas: St. Rose Hospital, Hayward, CA
May 30, 2015	How I treat Soft Tissue Sarcomas: CME presentation in conjunction with Annual Meeting, <i>ASCO 2015</i>
<i>Jan 25, 2017</i>	<i>New directions in treatment of soft tissue sarcoma for community oncologist: San Antonio, TX (CME)</i>
Jan 31, 2017	New directions in treatment of soft tissue sarcoma: Olive View-UCLA Medical Center, Sylmar, CA (CME)
Feb 1, 2017	Advances in Soft Tissue Sarcomas: Therapies to Interrupt Pathogenic Signaling Pathways: Online CME Webinar
Aug 30, 2017	Treatment of soft tissue sarcoma: Community Memorial Hospital, Ventura, CA (CME)
Sep 5, 2017	New therapies in soft tissue sarcoma: Olive View: UCLA Medical Center, Sylmar, CA (CME)
June 2, 2018	OncoLive Peer Exchange: Management of advanced soft tissue sarcomas
Oct 25, 2018	OncoLive: State of the science: Treatment of ovarian cancer and soft tissue sarcomas: Sheraton hotel, Palo Alto, CA (CME)
Feb 1, 2019	Advanced Soft Tissue Sarcomas in the Precision Medicine Era: Incorporating the latest advances into collaborative care. College Medical Center, Long Beach, CA (CME)
Mar 11, 2019	Grand Rounds: Soft Tissue Sarcoma. Loma Linda University Medical Center, Loma Linda, CA (CME)
Apr 17, 2019	Advanced Soft Tissue Sarcomas in the Precision Medicine Era: Incorporating the latest advances into collaborative care. University Medical Center of South Nevada, Las Vegas, NV (CME)
Apr 30, 2019	Grand Rounds: Soft Tissue Sarcoma. C Care Cancer center, Fresno, CA (CME)
May 21, 2019	Advanced Soft Tissue Sarcomas in the Precision Medicine Era: Incorporating the latest advances into collaborative care. Kootenai Clinic Cancer Services, Coeur d'Alene, ID (CME)
May 1, 2021	

- Jul 10, 2019 Advanced Soft Tissue Sarcomas in the Precision Medicine Era: Incorporating the latest advances into collaborative care. Reno Oncology Group, Reno, NV (CME)
- Aug 29, 2019 Grand Rounds: Soft Tissue Sarcoma. UCLA, Santa Monica, CA (CME)
- Oct 03, 2019 Grand Rounds: Soft Tissue Sarcoma. Sutter, Sacramento, CA (CME)
- Dec 12, 2019 Grand Rounds: Soft Tissue Sarcoma. Hope Health Center, Calabasas, CA (CME)
- Jul 06, 2020 Joint Decision-Making in the Treatment of Tenosynovial Giant Cell Tumors: Balancing Benefits and Risks. Online (CME)
- Sep 30, 2020 Solutions for Tenosynovial Giant Cell Tumors: Employing Effective Multimodal and Multidisciplinary Approaches to Patient Care. Online (CME)

PATIENT EDUCATION CONFERENCES

- Mar 9, 2018 Stanford Sarcoma Patient Education in collaboration with Sarcoma Foundation of America (LKS building)
Role: Planner and Speaker
- Aug 4, 2018 Stanford LMS Patient-Family Education in collaboration with National LMS Foundation (LKS building)
Role: Planner and Speaker
- Apr 13, 2019 Stanford Desmoid Patient Education in collaboration with Desmoid Tumor Research Foundation (So. San Francisco)
Role: Planner and Speaker

May 1, 2021